Login to Your Account

Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's

By Marie Powers
Staff Writer

Friday, January 25, 2013

Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications – spinal cord injury (SCI) and Alzheimer's disease (AD) – that have bedeviled biotechs and big pharmas, alike.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription